Literature DB >> 18923047

Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner.

Caroline L Benn1, Tingting Sun, Ghazaleh Sadri-Vakili, Karen N McFarland, Derek P DiRocco, George J Yohrling, Timothy W Clark, Bérengère Bouzou, Jang-Ho J Cha.   

Abstract

Transcriptional dysregulation is a central pathogenic mechanism in Huntington's disease, a fatal neurodegenerative disorder associated with polyglutamine (polyQ) expansion in the huntingtin (Htt) protein. In this study, we show that mutant Htt alters the normal expression of specific mRNA species at least partly by disrupting the binding activities of many transcription factors which govern the expression of the dysregulated mRNA species. Chromatin immunoprecipitation (ChIP) demonstrates Htt occupation of gene promoters in vivo in a polyQ-dependent manner, and furthermore, ChIP-on-chip and ChIP subcloning reveal that wild-type and mutant Htt exhibit differential genomic distributions. Exon 1 Htt binds DNA directly in the absence of other proteins and alters DNA conformation. PolyQ expansion increases Htt-DNA interactions, with binding to recognition elements of transcription factors whose function is altered in HD. Together, these findings suggest mutant Htt modulates gene expression through abnormal interactions with genomic DNA, altering DNA conformation and transcription factor binding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18923047      PMCID: PMC2586288          DOI: 10.1523/JNEUROSCI.2126-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  57 in total

1.  DNA condensation by the nucleocapsid protein of HIV-1: a mechanism ensuring DNA protection.

Authors:  G Krishnamoorthy; Bernard Roques; Jean-Luc Darlix; Yves Mély
Journal:  Nucleic Acids Res       Date:  2003-09-15       Impact factor: 16.971

Review 2.  Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle.

Authors:  Brigit E Riley; Harry T Orr
Journal:  Genes Dev       Date:  2006-08-15       Impact factor: 11.361

3.  Stable fluorescent complexes of double-stranded DNA with bis-intercalating asymmetric cyanine dyes: properties and applications.

Authors:  H S Rye; S Yue; D E Wemmer; M A Quesada; R P Haugland; R A Mathies; A N Glazer
Journal:  Nucleic Acids Res       Date:  1992-06-11       Impact factor: 16.971

4.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

Authors:  R Luthi-Carter; A Strand; N L Peters; S M Solano; Z R Hollingsworth; A S Menon; A S Frey; B S Spektor; E B Penney; G Schilling; C A Ross; D R Borchelt; S J Tapscott; A B Young; J H Cha; J M Olson
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

5.  Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice.

Authors:  Gabriele Schilling; Alena V Savonenko; Alexandra Klevytska; Johanna L Morton; Stina M Tucker; Michelle Poirier; Alexa Gale; Ning Chan; Vicky Gonzales; Hilda H Slunt; Michael L Coonfield; Nancy A Jenkins; Neal G Copeland; Christopher A Ross; David R Borchelt
Journal:  Hum Mol Genet       Date:  2004-06-09       Impact factor: 6.150

6.  SUMO modification of Huntingtin and Huntington's disease pathology.

Authors:  Joan S Steffan; Namita Agrawal; Judit Pallos; Erica Rockabrand; Lloyd C Trotman; Natalia Slepko; Katalin Illes; Tamas Lukacsovich; Ya-Zhen Zhu; Elena Cattaneo; Pier Paolo Pandolfi; Leslie Michels Thompson; J Lawrence Marsh
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

7.  CRE-mediated transcription is increased in Huntington's disease transgenic mice.

Authors:  Karl Obrietan; Kari R Hoyt
Journal:  J Neurosci       Date:  2004-01-28       Impact factor: 6.167

8.  Interference of Crx-dependent transcription by ataxin-7 involves interaction between the glutamine regions and requires the ataxin-7 carboxy-terminal region for nuclear localization.

Authors:  Shiming Chen; Guang-Hua Peng; Xuejiao Wang; Annette C Smith; Sara K Grote; Bryce L Sopher; Albert R La Spada
Journal:  Hum Mol Genet       Date:  2003-11-12       Impact factor: 6.150

9.  Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis.

Authors:  Katharine L Sugars; Rosemary Brown; Lynnette J Cook; Jina Swartz; David C Rubinsztein
Journal:  J Biol Chem       Date:  2003-11-18       Impact factor: 5.157

10.  Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes.

Authors:  Chiara Zuccato; Marzia Tartari; Andrea Crotti; Donato Goffredo; Marta Valenza; Luciano Conti; Tiziana Cataudella; Blair R Leavitt; Michael R Hayden; Tõnis Timmusk; Dorotea Rigamonti; Elena Cattaneo
Journal:  Nat Genet       Date:  2003-07-27       Impact factor: 38.330

View more
  85 in total

1.  Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Authors:  Xuesong Chen; Jun Wu; Yuan Luo; Xia Liang; Charlene Supnet; Mee Whi Kim; Gregor P Lotz; Guocheng Yang; Paul J Muchowski; Thomas Kodadek; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-09-23

2.  SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis.

Authors:  Ruth Luthi-Carter; David M Taylor; Judit Pallos; Emmanuel Lambert; Allison Amore; Alex Parker; Hilary Moffitt; Donna L Smith; Heike Runne; Ozgun Gokce; Alexandre Kuhn; Zhongmin Xiang; Michele M Maxwell; Steven A Reeves; Gillian P Bates; Christian Neri; Leslie M Thompson; J Lawrence Marsh; Aleksey G Kazantsev
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-08       Impact factor: 11.205

3.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

4.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Bin Tang; Alexandre Kuhn; SoongHo Kim; Daniel H Geschwind; Timothy B Brown; Ruth Luthi-Carter; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2010-12-20       Impact factor: 6.150

5.  Regulation of RE1 protein silencing transcription factor (REST) expression by HIP1 protein interactor (HIPPI).

Authors:  Moumita Datta; Nitai P Bhattacharyya
Journal:  J Biol Chem       Date:  2011-08-06       Impact factor: 5.157

Review 6.  Oligonucleotide therapeutic approaches for Huntington disease.

Authors:  Dinah W Y Sah; Neil Aronin
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 7.  Prospects for the development of epigenetic drugs for CNS conditions.

Authors:  Moshe Szyf
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

8.  High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntington's disease CAG knock-in mice across multiple genetic backgrounds.

Authors:  Seth A Ament; Jocelynn R Pearl; Andrea Grindeland; Jason St Claire; John C Earls; Marina Kovalenko; Tammy Gillis; Jayalakshmi Mysore; James F Gusella; Jong-Min Lee; Seung Kwak; David Howland; Min Young Lee; David Baxter; Kelsey Scherler; Kai Wang; Donald Geman; Jeffrey B Carroll; Marcy E MacDonald; George Carlson; Vanessa C Wheeler; Nathan D Price; Leroy E Hood
Journal:  Hum Mol Genet       Date:  2017-03-01       Impact factor: 6.150

9.  A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.

Authors:  Marianne R Smith; Adeela Syed; Tamas Lukacsovich; Judy Purcell; Brett A Barbaro; Shane A Worthge; Stephen R Wei; Giuseppe Pollio; Letizia Magnoni; Carla Scali; Luisa Massai; Davide Franceschini; Michela Camarri; Marco Gianfriddo; Enrica Diodato; Russell Thomas; Ozgun Gokce; S J Tabrizi; Andrea Caricasole; Bernard Landwehrmeyer; Liliana Menalled; Carol Murphy; Sylvie Ramboz; Ruth Luthi-Carter; Goran Westerberg; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-01-16       Impact factor: 6.150

10.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.